• B&K posted a net loss of RMB 121.92 million for the six months ended June 30, widening 40.6% year over year.
• Loss per share attributable to owners of the parent worsened to RMB 1.04, versus a 19.5% wider loss year over year.
• Research and development expenses rose to RMB 61.27 million, up 58.8% year over year.
• Cash and cash equivalents fell to RMB 535.85 million as of June 30, down 15.3% from Dec. 31.
• Pipeline updates included Pro-101-1 in a Phase IIIa China trial with 40 participants enrolled; Pro-101-2 completed Phase II enrollment in July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. B&K Corporation Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260814-12285171), on August 14, 2026, and is solely responsible for the information contained therein.